DigmBio

Focus: DigmBio is a Korean biotechnology company focused on developing oral therapies for oncology, operating at an early stage with a single clinical program.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About DigmBio

AI assessmentNot Hiring

No open roles listed right now. Follow DigmBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DM5167

Advanced Breast Cancer

Phase 1

Clinical Trials (1)

NCT07101601Study of DM5167 in Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for DigmBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to join a focused oncology biotech at ground level with potential for high career impact if oral drug platform gains traction
Specialized expertise in oral formulation and drug delivery could differentiate your skills in a crowded pharma market
Early-stage company may offer equity upside and cross-functional involvement not available at larger organizations

Watch Out For

Only one Phase 1 program in pipeline creates significant execution risk with limited runway visibility without disclosed funding or financial metrics
Zero active job openings and sparse public disclosures suggest limited hiring velocity and transparency challenges
Geographic isolation in South Korea may complicate talent acquisition, investor relations, and access to major pharma partnerships

Generated by Claude from DigmBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline